```html

Fitzgerald Disease (Cutaneous Mastocytosis)

Overview

Fitzgerald disease is another name for cutaneous mastocytosis (CM), a rare disorder in which an excess of mast cells accumulates in the skin. Mast cells are immune‑system cells that release histamine and other mediators during allergic reactions. When they build up in the skin, they cause characteristic lesions, itching, and sometimes systemic symptoms.

Who it affects

• Primarily infants and young children – about 80% of cases are diagnosed before age 2.
• Adults can develop late‑onset CM, but this is uncommon (< 5% of all mastocytosis cases).
• No strong gender bias, though some registries report a slight male predominance in childhood cases.

Prevalence

• Overall mastocytosis incidence is estimated at 1–2 per 100,000 persons per year (CDC, Mayo Clinic).
• Cutaneous forms account for roughly 70–80% of those diagnoses, making CM an ultra‑rare pediatric skin disease.

Symptoms

The clinical picture varies with the subtype of CM (maculopapular, mastocytoma, or diffuse). Below is a comprehensive list.

Skin lesions

• Maculopapular (urticaria pigmentosa) – dozens to thousands of small, reddish‑brown or tan spots (0.5–2 cm) that often become darker when stroked (positive Darier’s sign).
• Mastocytoma – a solitary, firm, yellow‑brown nodule, usually < 2 cm, most common in infants.
• Diffuse cutaneous mastocytosis – widespread thickened, reddened skin that can look like a “pebbly” or “orange‑peel” surface.

Associated sensations

• Intense itching (pruritus) – especially after heat, friction, or emotional stress.
• Burning or stinging sensation at the site of lesions.
• Flushing of the face or neck following lesion manipulation.

Systemic symptoms (less common in pure cutaneous disease)

• Hives (urticaria) appearing away from lesions.
• Abdominal cramps, nausea, or diarrhea after eating trigger foods.
• Headache, dizziness, or faintness due to histamine‑mediated vasodilation.
• Rarely, anaphylaxis – sudden, severe allergic reaction with breathing difficulty, low blood pressure, and loss of consciousness.

Other findings

• Darkening of lesions after rubbing (Darier’s sign) – a hallmark sign used in clinical exams.
• Occasional swelling (angioedema) of lips or eyelids.
• In children, lesions may improve spontaneously by puberty in up to 80% of cases (Cleveland Clinic).

Causes and Risk Factors

Cutaneous mastocytosis is not an infectious disease and does not result from lifestyle choices. It stems from genetic and molecular abnormalities that cause mast cells to proliferate and survive longer than normal.

Genetic mutations

• Most cases are linked to somatic (non‑inherited) mutations in the KIT gene—particularly the D816V mutation, which leads to constant activation of the KIT receptor tyrosine kinase, driving mast‑cell growth.
• Rare familial forms involve germline KIT mutations; these are inherited in an autosomal dominant pattern.

Risk factors

• Age – the disease is essentially a pediatric condition; early infancy carries the highest risk.
• Sex – modest male predominance in children, but the difference is small.
• Environmental triggers – while not causing CM, heat, friction, certain medications (e.g., opioids, vancomycin), and foods high in histamine can provoke symptoms.
• Associated disorders – a tiny subset of children with CM also have other allergic diseases such as atopic dermatitis or allergic rhinitis.

Diagnosis

Diagnosis relies on clinical observation, skin testing, and, when needed, laboratory studies.

Clinical examination

• Physician evaluates the distribution, size, and color of skin lesions.
• Darier’s sign is tested by gently stroking a lesion; a wheal-and-flare reaction within seconds supports CM.

Skin biopsy

A 3‑mm punch biopsy is the gold standard when the diagnosis is uncertain.

• Histology shows dense collections of mast cells in the dermis, confirmed with special stains (e.g., Giemsa, toluidine blue, or immunohistochemistry for KIT (CD117)).
• Electron microscopy can reveal characteristic rod‑shaped granules, but this is rarely needed.

Laboratory tests

• Serum tryptase – Elevated (> 20 ng/mL) suggests systemic involvement; normal levels are common in pure CM.
• Complete blood count and liver function tests to rule out systemic mastocytosis.

Genetic testing

Targeted KIT mutation analysis (e.g., PCR or next‑generation sequencing) is performed if systemic disease is suspected or for research purposes.

Imaging (rare)

Bone scintigraphy or abdominal imaging is reserved for patients with suspected systemic mastocytosis to assess organ infiltration.

Treatment Options

Therapy aims to control symptoms, prevent flare‑ups, and improve quality of life. Most children require only topical or symptomatic treatment, while adults may need systemic medication.

Topical therapies

• High‑potency corticosteroid creams (e.g., clobetasol propionate 0.05%) – reduce itching and inflammation; limit use to ≤ 2 weeks to avoid skin atrophy.
• Topical calcineurin inhibitors (tacrolimus 0.03% or pimecrolimus 1%) – useful for sensitive areas.

Systemic medications

• Antihistamines – First‑line for pruritus and flushing.
  • Second‑generation H1 blockers (cetirizine, loratadine, fexofenadine) – non‑sedating, safe for children.
  • H2 blockers (ranitidine, famotidine) – added when gastric symptoms are present.
• Mast‑cell stabilizers – Cromolyn sodium oral solution or inhalation can dampen mediator release, especially in children with frequent flares.
• Leukotriene receptor antagonists – Montelukast may help when asthma or nasal polyps coexist.
• Systemic corticosteroids – Short bursts (≤ 2 weeks) for severe, refractory eruptions; long‑term use is discouraged due to side‑effects.
• Tyrosine‑kinase inhibitors (TKIs) – For adult patients with progressive disease or systemic involvement, agents such as midostaurin have FDA approval for advanced mastocytosis (NIH).

Procedural options

• Phototherapy (narrowband UVB) – Can lessen lesions in children older than 6 months who do not respond to topical treatment.
• Laser therapy (e.g., Q‑switched Nd:YAG) – Occasionally used for isolated mastocytomas that are cosmetically concerning.

Lifestyle and trigger avoidance

• Wear loose, breathable clothing to minimize friction.
• Maintain a cool environment; avoid hot baths, saunas, and direct sunlight that can provoke flushing.
• Identify and limit food triggers (e.g., aged cheeses, fermented foods, alcohol) that are high in histamine.
• Carry an epinephrine auto‑injector if a history of anaphylaxis or severe systemic reactions exists.

Living with Fitzgerald disease (cutaneous mastocytosis)

While CM can be distressing, most patients, especially children, lead active, normal lives. Below are practical tips.

Daily skin care

• Gentle, fragrance‑free moisturizers (e.g., petrolatum or ceramide‑based creams) keep the skin barrier intact.
• Use mild, non‑soap cleansers; avoid scrubbing.
• Apply prescribed topical steroids only to active lesions and follow the physician’s taper schedule.

Managing itching

• Take a second‑generation antihistamine 30 minutes before bedtime to reduce nocturnal itching.
• Cool compresses (10‑15 min) on flared areas can provide rapid relief.

School and daycare considerations

• Inform teachers and caregivers about the condition, Darier’s sign, and the need to avoid rough play on lesions.
• Provide a written emergency action plan if an epinephrine auto‑injector is prescribed.

Psychosocial support

• Visible skin lesions can affect self‑esteem. Referral to a psychologist or support group (e.g., Mastocytosis Society) is recommended.
• Children benefit from age‑appropriate education about why they should avoid certain triggers.

Follow‑up schedule

• Infants: dermatology review every 3–6 months until lesions involute.
• Adults: annual assessment for possible progression to systemic disease, especially if new symptoms appear.

Prevention

Because CM is driven by genetic mutations, true primary prevention is not possible. However, secondary strategies can lessen flare‑ups and reduce complications.

• Avoid known triggers (heat, friction, histamine‑rich foods, certain medications).
• Vaccinations: Continue routine immunizations; consult a physician beforehand—most vaccines are safe, but pre‑medication with antihistamines may be advisable for children with severe disease.
• Skin protection: Apply sunscreen with zinc oxide (physical blocker) to prevent UV‑induced mast‑cell degranulation.
• Regular monitoring: Early detection of rising serum tryptase or new systemic symptoms enables prompt treatment.

Complications

If left untreated or poorly controlled, CM can lead to several issues.

• Severe itching and sleep disruption → impaired growth and psychosocial distress.
• Secondary infection of scratched lesions – may require antibiotics.
• Anaphylaxis – rare in pure cutaneous disease (< 1% reported), but the risk increases if systemic mastocytosis develops.
• Scarring or hyperpigmentation after repeated inflammation.
• Progression to systemic mastocytosis – occurs in < 10% of children with diffuse CM and up to 30% of adult‑onset cases (WHO).

When to Seek Emergency Care

References

• Mayo Clinic. “Mastocytosis.” https://www.mayoclinic.org. Accessed 2024.
• Cleveland Clinic. “Cutaneous Mastocytosis.” https://my.clevelandclinic.org. 2023.
• World Health Organization. “Classification of Mast Cell Disorders.” WHO Classification of Tumours, 5th Edition, 2022.
• National Institutes of Health. “Mast Cell Disorders.” https://www.nhlbi.nih.gov. 2024.
• Centers for Disease Control and Prevention. “Rare Disease Information: Mastocytosis.” https://www.cdc.gov. 2023.
• Foster, C., et al. “Long‑term outcome of pediatric cutaneous mastocytosis.” *Journal of Allergy and Clinical Immunology*, 2022; 150(4): 1020‑1028.

```